HOME
>
基礎医学
>
病理学
> 癌診療指針のための病理診断プラクティス　肺癌

癌診療指針のための病理診断プラクティス　肺癌

出版社：	中山書店
著者：	青笹克之(総編集) 松原修(専門編集)
発行日：	2011-05-02
分野：	基礎医学 > 病理学
ISBN：	9784521733333
シリーズ：	癌診療指針のための病理診断プラクティス
電子書籍版：	2011-05-02 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

19,800 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

商品紹介

腫瘍の診断において中心的役割をつとめる病理診断は，画像医学の進歩とともにその重要性を増している。本書では，病理医，臨床医が互いに理解を深められるよう，病理診断の基本を解説。また，鑑別診断の章では疾患別にフローチャートを用意して，鑑別すべき病理像も豊富に掲載し，病理医だけでなく，臨床医にも活用しやすい，実用のための書籍となっている。

目次

癌診療指針のための病理診断プラクティス　肺癌

―目次―

1章　病理診断の流れとポイント
2章　診断のための基本知識
3章　肺疾患の概要と鑑別診断
4章　胸膜腫瘍の概要と鑑別診断
5章　アスベスト症の概要と鑑別診断
6章　病理検体の取り扱い
7章　症例の実際

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

2章診断のための基本知識

P.14 掲載の参考文献

・江口研二編. 肺癌治療マニュアル. 初版. 東京 : 中外医学社 ; 2006. p.46-60.

・ Lorentz GBA, et al. Miss rate of lung cancer on the chest radiograph in clinical practice. Chest. 1999 ; 115 : 720-4.

・ Austin JHM, et al. Missed bronchogenic carcinoma : radiographic findings in 27 patients with a potentially respectable lesion evident in retrospect. Radiology. 1992 ; 182 : 115-22.

・ Shah PK, et al. Missed non-small cell lung cancer : radiographic findings of potentially resectable lesions evident only in retrospect. Radiology. 2003 ; 226 : 235-41.

・黒崎敦子ほか. 胸部単純写真の読み方 ; 高分解能CT及び病理所見との対比. 肺癌. 2003 ; 43 : 791-8.

・森拓二ほか. 肺がんの進展様式とX線診断. 総合臨床. 1982 ; 31 : 1801-5.

・松島敏春, 江口研二ほか編. 明解画像診断の手引き. 東京 : 国際医学出版 ; 2003. p.90-100.

・ Godoy MCB, et al. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung : recommended interim guidelines for assessment and management. Radiology. 2009 ; 253 : 606-22.

・ Aoki T, et al. Peripheral lung adenocarcinoma : correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 2001 ; 220 : 803-9.

・ Adler B, et al. High-resolution CT of bronchioloalveolar carcinoma. AJR. 1992 ; 159 : 257-77.

・ Im JG, et al. Lobar bronchioloalveolar carcinoma : 'angiogram sign' on CT scans. Radiology. 1990 ; 176 : 749-53.

・ Travis WD, et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35cases. Am J Surg Pathol. 1991 ; 15 : 529-53.

・ World Health Organization. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin : Springer Germany ; 1999.

・ Semin Chong MD, et al. Neuroendocrine tumors of the lung : clinical, pathologic, and imaging findings. Radiographics. 2006 ; 26 : 41-58.

・ Oshiro Y, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR. 2004 ; 182 : 87-91.

P.19 掲載の参考文献

・ Lardinois D, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003 ; 348 : 2500-7.

・ Wahl RI, et al. Staging of mediastinal non-small-cell lung cancer with FDG PET CT, and fusion images : preliminary prospective evaluation. Radiology. 1994 ; 19 (2) : 371-7.

・ Pieterman RM, et al. Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med. 2000 ; 343 : 254-61.

・ Vessels H, et al. The impact of fluorodeoxyglucose F18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovalc Surg. 2002 ; 124 (3) : 511-9.

・ Lee JW, et al. 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country : consideration of lymph node calcification and distribution pattern to improve specificity. Eur J Nucl Med Mol Imaging. 2009 ; 36 : 1794-802.

・ Hellwig D, et al. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie. 2001 ; 55 : 367-77.

・ van Tinteren H, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer. The PLUS multicenter randomized trial. Lancet. 2002 ; 359 : 1388-93.

・ Cerfolio RJ, et al. The maximum standard uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005 ; 130 : 151-9.

・ Burry T, et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J. 1999 ; 14 : 1376-80.

・ Hellwig D, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006 ; 33 : 1376-80.

・ Brink I, et al. Impact of [18F] FDG-PET on the primary staging of small cell lung cancer. Eur J Nucl Med Mol Imaging. 2004 ; 31 : 1614-20.

・ Erasmus JJ, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma : staging implications. J Thorac Cardiovasc Surg. 2005 ; 129 : 1364-70.

P.26 掲載の参考文献

・ Banks DE, et al. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison group. Am Rev Respir Dis. 1990 ; 141 : s169-97.

・ Drent M, et al. Bronchoalveolar lavage, Diffuse parenchymal lung disease. Prog Respir Res. 2007 ; 36 : 58-67.

・ Pirozynski M. Bronchoalveolar lavage in the diagnosis of peripheral, primary lung cancer. Chest. 1992 ; 102 : 372-4.

・ Semenzato G, Poletti V. Bronchoalveolar lavage in lung cancer. Respiration 1992 ; 59 (suppl 1) : 44-6.

・ Pina CT, et al. Tumour markers in serum, bronchoalveolar lavage and biopsy cytosol in lung carcinoma : what environment lends the optimum diagnostic yield. Clinica Chimica Acta. 2001 ; 305 : 27-34.

・ De Diego A, et al. Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. A comparative study among patients with peripheral lung cancer, pneumonia, and healthy individuals. Chest. 1991 ; 100 : 1060-3.

・日本呼吸器学会びまん性肺疾患学術部会, 厚生労働省難治性疾患克服研究事業びまん性肺疾患調査研究班編. 気管支肺胞洗浄 [BAL] 法の手引き. 東京 : 克誠堂出版 ; 2008.

P.31 掲載の参考文献

・日本乳癌学会編. 臨床・病理乳癌取扱い規約 (第16版). 東京 : 金原出版 ; 2008.

・甲状腺外科検討会編. 甲状腺癌取扱い規約 (第6版). 東京 : 金原出版 ; 2005.

・日本肺癌学会編. 臨床・病理肺癌取扱い規約 (第7版). 東京 : 金原出版 ; 2010.

・ Noguchi M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995 ; 95 : 41-5.

・ Satoh Y, et al. Association of cytologic micropapillary clusters in cytology samples with lymphatic spread in clinical stage I lung adenocarcinomas. Lung Cancer. 2009 ; 64 : 277-81.

・ Iyoda A, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001 ; 91 : 1992-2000.

・ Kakinuma H, et al. Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas. Comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas. Cancer Cytopathol. 2003 ; 99 : 247-54.

・ Hoshi R, et al. Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung. J Thorac Oncol. 2010 ; 5 : 472-8.

P.41 掲載の参考文献

・日本肺癌学会編. EBM 手法による肺癌診療ガイドライン. 東京 : 金原出版 ; 2005. p.7-9.

・日本肺癌学会編. 臨床・病理肺癌取扱い規約. 東京 : 金原出版 ; 2003. p.86-7.

・於保健吉, 雨宮隆太編. 気管支ファイバースコピー. 東京 : 医学書院 ; 1994. p.121-6, 208-16.

・下里幸雄編. 肺癌の生検と細胞診. 東京 : 医学書院 ; 1988. p.10.

・池田徳彦. 新しい手法を用いた肺癌の早期診断と今後の展望. 北里医学. 2009 ; 39 : 87-94.

・ Yasufuku K, Nakajima T, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006 ; 130 : 710-8.

・国立がんセンター編. 臨床肺癌 II. 東京 : 講談社 ; 1983. p218-9.

・安福和弘, 安田一朗監修. 超音波内視鏡による縦隔領域へのアプローチ. 東京 : オリンパスメディカルシステムズ協力. p.3.

・安田一朗, 森脇久隆. 縦隔病変のEUS診断. 臨床消化器内科. 2005 ; 20 : 1573-80.

・中谷行雄, 野口雅之編. 肺・胸膜腫瘍 II. 病理と臨床. 2010 ; 28 : 227-37.

・石田敦子ほか. 胸腔鏡. 気管支学. 2009 ; 31 : 328-33.

・藤村重文編. 呼吸器腫瘍外科学. 東京 : 南江堂 ; 1999. p.83-4.

・中澤賢ほか. CTNBの実際. 臨床画像. 2010 ; 26 : 170-81.

・石井源一郎. 肺腫瘤性病変迅速診断のpitfall. 病理と臨床. 2010 ; 28 : 234-7.

P.51 掲載の参考文献

・ UICC International Union Against Cancer. TNM Classification of Malignant Tumours. 7th ed. New York : Wiley-Liss ; 2009.

・ Goldstraw P, et al. The IASLC lung cancer staging project : proposal for the revision of TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007 ; 2 : 706-14.

・ UICC International Union Against Cancer. TNM Classification of Malignant Tumours, 6th ed. New York : Wiley-Liss ; 2002.

・日本肺癌学会編. 臨床・病理肺癌取扱い規約 (抜粋) (改定第7版案). 肺癌. 2009 ; 49 別冊.

・ Hsu PK, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann thorac Surg. 2007 ; 84 : 1825-9.

・ Travis WD, et al. Visceral pleural invasion : pathologic criteria and use of elastic stains : proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008 ; 3 : 1384-90.

・ Martini N, Melamed MR. Multiple primary cancers. J Thorac Cardiovasc Surg. 1975 ; 70 : 606-12.

・ Matsuzoe D, et al. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer. 1999 ; 79 : 1549-52.

・ Girard N, et al. Use of EGFR/KRAS mutation testing to define clonal relationships among multiple lung adenocarcinomas. Chest. 2010 ; 137 : 46-52.

P.58 掲載の参考文献

・日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2005年版. 東京 : 金原出版 ; 2005.

・日本肺癌学会編. 臨床・病理肺癌取扱い規約 (第6版). 東京 : 金原出版 ; 2003.

・日本肺癌学会編. 臨床・病理肺癌取扱い規約 (第7版). 東京 : 金原出版 ; 2010.

・ Goldstraw P, Crowley J, et al. International Association for the Study of Lung Cancer International Staging Committee ; Participating Institutions. The IASLC Lung Cancer Staging Project : proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007 ; 2 : 706-14.

・ Noguchi M, Morikawa A, et al. Small adenocarcinoma of the lung. Cancer. 1995 ; 75 : 2844-52.

・ Yoshikawa K, Tsubota N, et al. Prospective study of extended segmentectomy for small lung tumors : The final report. Ann Thorac Surg. 2002 ; 73 : 1055-59.

・ Rusch VW, Giroux DJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus : Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001 ; 121 : 472-83.

・ Arriagada R, Bergman B,. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 ; 350 : 351-60.

・ Kato H, Ichinose Y, et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004 ; 350 : 1713-21.

・伊豫田明. 3学会合同呼吸療法認定士「認定更新のための講習会」テキスト-術後管理における感染対策-. 3学会合同呼吸療法認定士認定委員会事務局. 2010. p.10-7.

・下方薫, 蘇原泰則. 1999年肺癌外科切除例の全国集計に関する報告. 肺癌. 2007 ; 47 : 299-311.

・ Kris MG, Natale RB, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : A randomized trial. JAMA. 2003 ; 290 : 2149-58.

・ Fukuoka M, Yano S, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 ; 21 : 2237-46.

・ Johnson DH, Fehrenbacher L, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 ; 22 : 2184-91.

・ World Health Organization. Histological Typing of Lung and Pleural Tumours. Third Edition. Springer Germany. 1999.

・ Iyoda A, Hiroshima K, et al. Pulmonary large cell neuroendocrine carcinoma : its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg. 2007 ; 84 : 702-7.

・ Iyoda A, Hiroshima K, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathological stage 1a pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg. 2006 ; 132 : 312-5.

・ Iyoda A, Hiroshima K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006 ; 82 : 1802-7.

P.64 掲載の参考文献

・日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2005年版. 東京 : 金原出版 ; 2005.

・ ASCO Clinical Practice Guideline Update on Chemotherapy for Stage IV NSCLC. J Clin Oncol. 2009 ; 27 : 6251-66.

・ Mok T, Wu Y, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009 ; 361 : 947-57.

・ Soda M, Choi YL, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 ; 448, 561-6.

P.77 掲載の参考文献

・原田邦彦. 肺癌に対する光線力学的治療-光線力学的治療の進歩と非小細胞肺癌に対する適応拡大-. 肺癌. 2005 ; 45 : 687-92.

・ Usuda J, Tsutsui H, et al. Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluoresence bronchoscopy. Lung Cancer. 2007 ; 58 : 317-23.

・ Okada M, Koike T, et al. Radical sublobar resection for small-sized non-small cell lung cancer : a multi-center study. J Thoracic Cardiovasc Surg. 2006 ; 132 : 769-75.

・ Ichinose J, Kohno T, et al. Locoregional control of thoracoscopic lobectomy with selective lymphadenectomy for lung cancer. Ann Thorac Surg. 2010 ; 90 : 235-9.

・ Mun M, Kohno T. Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground glass opacities of 20 mm or less in diameter. J Thorac Cardiovasc Surg. 2007 ; 134 : 877-82.

P.82 掲載の参考文献

・ Fukuoka M, Yano S, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 ; 21 : 2237-46.

・ Kris MG, Natale RB, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial. JAMA. 2003 ; 290 : 2149-58.

・ Lynch TJ, Bell DW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 ; 350 : 2129-39.

・ Paez JG, Janne PA, et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science. 2004 ; 304 : 1497-500.

・ Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002 ; 297 : 63-4.

・ Yun CH, Boggon TJ, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes : mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007 ; 11 : 217-27.

・ Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007 ; 98 : 1817-24.

・ Yatabe Y, Kosaka T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005 ; 29 : 633-9.

・ Toyooka S, Yatabe Y, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer. 2006 ; 118 : 1588-90.

・ Tatematsu A, Shimizu J, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 2008 ; 14 : 6092-6.

・ Soda M, Choi YL, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 ; 448 : 561-6.

・ Mano H. Non-solid oncogenes in solid tumors : EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008 ; 99 : 2349-55.

・ Inamura K, Takeuchi K, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009 ; 22 : 508-15.

・ Shigematsu H, Takahashi T, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005 ; 65 : 1642-6.

・ Cappuzzo F, Bemis L, et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006 ; 354 : 2619-21.

・ Sandler A, Gray R, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50.

・ Reck M, von Pawel J, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil. J Clin Oncol. 2009 ; 27 : 1227-34.

・ Hynes NE, Lane HA. ERBB receptors and cancer : the complexity of targeted inhibitors. Nat Rev Cancer. 2005 ; 5 : 341-54.

・ Morita S, Okamoto I, et al. Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations. Clin Cancer Res 2009 ; 15 : 4493-8.

・ Lee JS, Park K, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009 ; 4 (Suppl 1) : S283 (abstr PRS.4).

3章肺疾患の概要と鑑別診断

P.88 掲載の参考文献

・ Mark EJ. Lung Biopsy Interpretation. Baltimore : Williams & Wilkins ; 1984. p.113-30.

・ Liebow AA. New concepts and entities in pulmonary disease. In : Liebow AA, Smith DE, editors. The Lung. Baltimore : Williams & Wilkins ; 1968. p.332-65.

・ ATS/ERS International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit care Med. 2002 ; 165 : 277-304.

・松原修, 大河内康実ほか. 間質性肺炎の見方 : 病理組織反応の型と原因について. 病理と臨床. 2000 ; 18 : 241-7.

・ Corrin B, Nicholson AG. Pathology of the Lungs. 2nd ed. Churchill Livingstone : Elsevier ; 2006.

P.100 掲載の参考文献

・ Travis WD, et al. Histological typing of lung and pleural tumours, World Health Organization International Histological Classification of Tumours. 3rd ed. Berlin : Springer ; 1999.

・ Mao L, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 ; 89 : 857-62.

・坂下信吾ほか. 前癌病変と非浸潤癌. 医学のあゆみ. 2008 ; 224 (13) 1025-9.

・ Auerbach O, et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med. 1961 ; 265 : 253-67.

・ Auerbach O, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung ; a report of progress. N Engl J Med. 1957 ; 256 : 97-104.

・ Lam S, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998 ; 113 : 696-702.

・ Shibuya K, et al. Increased telomerase activity and elevated hTERT mRNA expression during multistage carcinogenesis of squamous cell carcinoma of the lung. Cancer. 2001 ; 92 : 849-55.

・ Lantuejoul S, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res. 2005 ; 11 : 2074-82.

・ Lantuejoul S, et al. Pulmonary preneoplasia--sequential molecular carcinogenetic events. Histopathology. 2009 ; 54 : 43-54.

・ Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol. 2001 ; 54 (4) : 257-71.

・下里幸雄, 井内康輝編. 腫瘍鑑別診断アトラス肺. 第2版. 東京 : 文光堂 ; 2004.

・ Yatabe Y, et al. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002 ; 26 : 767-73.

・ Kitagawa H, et al. A clinicopathological study with special reference to smoking and cancer multiplicity. Pathol Int. 2003 ; 53 : 823-7.

・ Chapman KD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer. 2000 ; 83 : 632-6.

・ Suzuki K, et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia : a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer. 1997 ; 79 : 1521-6.

・ Sakuma Y, et al. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol. 2007 ; 20 : 967-73.

・ Yoo SB, et al. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol. 2010 ; 5 : 964-9.

・ Sakamoto H, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol. 2007 ; 212 : 287-94.

・ Chung JH, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol. 2009 ; 4 : 1490-5.

・ Kozuki T, et al Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer. 2007 ; 58 : 30-5.

P.110 掲載の参考文献

・ Sandler A, Gray R, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50.

・ Scagliotti GV, Parikh P, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26 : 3543-51.

・ Asamura H, Goya T, et al. A Japanese Lung Cancer Registry study : prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008 ; 3 : 46-52.

・ Sawabata N, Asamura H, et al. Japanese Lung Cancer Registry Study : first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol. 2010 ; 5 : 1369-75.

・ Funai K, Yokose T, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003 ; 27 : 978-84.

・ Zhang H, Liu J, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma : an immunohistochemical approach. Mod Pathol. 2005 ; 18 : 111-8.

・ Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung : a comparative study. Mod Pathol. 2006 ; 19 : 417-28.

・ Sholl LM, Long KB. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2010 ; 18 : 55-61.

・ Monica V, Ceppi P, et al. Desmocollin-3 : a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009 ; 22 : 709-17.

・ Rossi G, Marchioni A, et al. TTF-1, cytokeratin 7, 34bE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004 ; 122 : 884-93.

P.120 掲載の参考文献

・ Travis WD, Brambilla E, et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon : IARC press ; 2004.

・ Noguchi M, Morikawa A, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995 ; 75 : 2844-52.

・ Travis WD, Brambilla E, et al. IASLC/ATS/ERS International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. in press.

・ Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010 ; 29 : 23-36.

・ Kurokawa T, Matsuno Y, et al. Surgically curable "early" adenocarcinoma in the periphery of the lung. Am J Surg Pathol. 1994 ; 18 : 431-8.

・ Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu. 1988 ; 23 Pt 2 : 361-94.

・ Edwards CW. Pulmonary adenocarcinoma : review of 106 cases and proposed new classification. J Clin Pathol. 1987 ; 40 : 125-35.

・ Ebright MI, Zakowski MF, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma, The Annals of thoracic surgery 2002 ; 74 : 1640-46 ; discussion 1646-47.

・ Miller VA, Riely GJ, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 ; 26 : 1472-8.

・ Mok TS, Wu YL, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 ; 361 : 947-57.

・ Mitsudomi T, Morita S, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol. 2010 ; 11 : 121-8.

・ Maemondo M, Inoue A, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 ; 362 : 2380-8.

・ Johnson DH, Fehrenbacher L, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 ; 22 : 2184-91.

・ Cohen MH, Gootenberg J, et al. FDA drug approval summary : bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007 ; 12 : 713-8.

・ Sandler A, Gray R, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50.

・ Reck M, von Pawel J, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil. J Clin Oncol. 2009 ; 27 : 1227-34.

・ Scagliotti GV, Parikh P, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26 : 3543-51.

・ Shaw AT, Yeap BY, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 ; 27 : 4247-53.

・ Rodig SJ, Mino-Kenudson M, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 ; 15 : 5216-23.

・ Sica G, Yoshizawa A, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010 ; 34 : 1155-62.

・ Nakazato Y, Minami Y, et al. Nuclear grading of primary pulmonary adenocarcinomas : correlation between nuclear size and prognosis. Cancer. 2010 ; 116 : 2011-9.

・ Burks RT, Sherman ME, et al. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996 ; 20 : 1319-30.

・ Moran CA. Pulmonary adenocarcinoma : the expanding spectrum of histologic variants. Arch Pathol Lab Med. 2006 ; 130 : 958-62.

・ Yatabe Y, Mitsudomi T, et al. TTF-1 Expression in Pulmonary Adenocarcinomas. Am J Surg Pathol. 2002 ; 26 : 767-73.

・ Graham AD, Williams AR, et al. TTF-1 expression in primary ovarian epithelial neoplasia. Histopathology. 2006 ; 48 : 764-5.

・ Siami K, McCluggage WG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007 ; 31 : 1759-63.

P.140 掲載の参考文献

・ Govindan R, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of surveillance, epidemiologic, and end results database. JCO. 2006 ; 24 (28) : 4539-44.

・ IARC WHO Classification Tumors of the Lung, Pleura, Thymus and Heart. 2004.

★ M Puglisi, et al. Treatment options for small cell lung cancer-do we have more choice? BJC. 2010 ; 102 : 628-38.

・ Detterbeck FC, et al. The new lung cancer staging system. Chest. 2009 ; 136 : 260-71.

★ Mary Beth Beasley : Immunohistochemistry of Pulmonary and Pleural Neoplasia Arch Pathol Lab Med. 2008 ; 132 : 1062-72.

・ Kobayashi Y, Tokuchi Y, et al. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci. 2004 ; 95 (4) : 334-41.

★ Samuel P. Hammar, Sanja Dacic. Immunohistology of Lung and Pleural Neoplasms. In : David J Dabbs, editor. Diagnostic Immunohistochemistry Theranostic and Genomic Applications 3rd ed. Saunders Elsevier. 2010 : 369-96.

★ Rira Hoshi, et al. Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung. JTO. 2010 ; 5 : 472-8.

・ Travis William D, et al. The IASLC lung cancer staging project : proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) Edition of the TNM classification for lung cancer. JTO. 2008 ; 3 (11) : 1213-23.

・下里幸雄, 井内康輝. 小細胞肺癌. 腫瘍鑑別診断アトラス肺第2版. 東京 : 文光堂 ; 2004. p.98-113.

・深山正久ほか. 病理と臨床診断に役立つ免疫組織化学. 東京 : 文光堂 ; 2007. 臨時増刊号 Vol.25.

P.149 掲載の参考文献

・日本肺癌学会編. 臨床・病理肺癌取扱い規約 (改訂第7版), 東京 : 金原出版, 2010.

・後藤明輝, 深山正久. 大細胞癌の組織診断 (大細胞神経内分泌癌を除く). 病理と臨床. 2010 ; 28 (2) : 156-61.

・ Borczuk AC, et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003 ; 163 : 1949-60.

・ MacArthur AC, et al. Identification of occupational cancer risk in British Columbia : a population-based case-control study of 2,998 lung cancers by histopathological subtype. Am J Ind Med. 2009 ; 52 (3) : 221-32.

・大場岳彦, 石川雄一 : 肺神経内分泌腫瘍の分類と組織診断. 病理と臨床. 2010 : 28 (2) : 151-5.

・後藤明輝, 深山正久 : リンパ上皮腫様. 深山正久ほか編. 病理形態学キーワード. 東京 : 文光堂 ; 2010 : p.56-7.

・廣島健三, 中谷行雄. 肺肉腫様癌の分類と組織診断. 病理と臨床. 2010 : 28 (2) : 162-9.

P.158 掲載の参考文献

・ Fishback NF, et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 1994 ; 73 : 2936-45.

・ Hasleton P. Sarcomatoid carcinoma : Pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. In : Tomashefski JF Jr, et al. editors. Dail and Hammar's Pulmonary Pathology. New York : Springer ; 2008. p. 375-97.

・ Koss MN, et al. Carcinosarcomas of the lung : a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999 ; 23 : 1514-26.

・ Koss MN, et al. Pulmonary blastomas. Cancer. 1991 ; 67 : 2368-81.

・ Nakatani Y, et al. Aberrant nuclear/cytoplasmic localization and gene mutation of betacatenin in classic pulmonary blastoma : beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol. 2004 ; 28 : 921-7.

・廣島健三, 中谷行雄. 肺肉腫様癌の分類と組織診断. 肺・胸膜腫瘍 I 分類と診断UPDATE. 病理と臨床. 2010 ; 28 : 162-9.

・ Pelosi G, Sonzogni A, et al. Pulmonary sarcomatoid carcinoma : A practical review. Int J Surg Pathol. 2010 ; 18 : 103-20.

・ Nakatani Y, Hiroshima K, et al. Sarcomatoid carcinoma. In : Hasleton P, Flieder D, editors. Spencer's Pathology of the Lung. 6th ed. Cambridge University Press ; in press.

P.170 掲載の参考文献

・ Arrigoni MG, et al. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972 ; 64 : 413-21.

・ Travis WD, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 ; 15 : 529-53.

・ Travis W, et al., editors. World Health Organization. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin : Springer-Verlag ; 1999.

・ Travis W, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC Press ; 2004.

・ Abdi EA, et al. Peripheral carcinoid tumours of the lung : a clinicopathological study. J Surg Oncol. 1988 ; 39 : 190-6.

・ Beasley MB, et al. Pulmonary atypical carcinoid : predictors of survival in 106 cases. Hum Pathol. 2000 ; 31 : 1255-65.

・ Sajjad SM, et al. Oncocytic carcinoid tumor of the lung. Ultrastruct Pathol. 1980 ; 1 : 171-6.

・ Grazer R, et al. Melanin-containing peripheral carcinoid of the lung. Am J Surg Pathol. 1982 ; 6 : 73-8.

・ Carlson JA, Dickersin GR. Melanotic paraganglioid carcinoid tumor : a case report and review of the literature. Ultrastruct Pathol. 1993 ; 17 : 353-72.

・ Folpe AL, et al. Thyroid transcription factor-1 : immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999 ; 12 : 5-8.

・ Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000 ; 36 : 415-20.

・ Sturm N, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol. 2002 ; 33 : 175-82.

・ Hiroshima K, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma : a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006 ; 19 : 1358-68.

・ Debelenko LV, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997 ; 6 : 2285-90.

・ Onuki N, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999 ; 85 : 600-7.

・ Iyoda A, et al. Pulmonary large cell carcinomas with neuroendocrine features are highgrade neuroendocrine tumors. Ann Thorac Surg. 2002 ; 73 : 1049-54.

・ Asamura H, et al. Neuroendocrine neoplasms of the lung : a prognostic spectrum. J Clin Oncol. 2006 ; 24 : 70-6.

・ Travis WD, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998 ; 22 : 934-44.

・ Thomas CF Jr., et al. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest. 2001 ; 119 : 1143-50.

・ Bertino EM, et al. Pulmonary neuroendocrine/carcinoid tumors : a review article. Cancer. 2009 ; 115 : 4434-41.

・ Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010 ; 89 : 998-1005.

P.197 掲載の参考文献

・ Wick MR, et al. Pseudoneoplastic lesions of the lung and pleural surfaces. In : Leslie KO, Wick MR, editors. Practical Pulmonary Pathology, a diagnostic approach. Philadelphia : Churchill Livingstone, et al. ; 2005, 649-72.

・ Coffin CM, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001 ; 14 : 569-76.

・ Cook JR, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor : a comparative immunohistochemical study. Am J Surg Pathol. 2001 ; 25 : 1364-71.

・ Zen Y, et al. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum Pathol. 2005 ; 36 : 710-7.

・米盛葉子ほか. 炎症性偽腫瘍lymphoplasmacytic sclerosing variantはIgG4関連systemic fibrosing diseaseに属する. 日病会誌 2007 ; 96 : 345.

P.209 掲載の参考文献

・ Gregori-Romero MA, et al. Recombinations of chromosomal bands 10q24, 12q14-q15, and 14q24 in two cases of pulmonary chondroid hamartoma studied by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2003 ; 142 : 153-7.

・ Muraoka M, et al. Endobronchial lipoma : review of 64 cases reported in Japan. Chest. 2003 ; 123 : 293-6.

・亀田陽一. 硬化性血管腫・乳頭腫・腺腫. 病理と臨床. 2010 ; 28 : 263-72.

・ Keylock JB, et al. Sclerosing hemangioma of the lung. Arch Pathol Lab Med. 2009 ; 133 : 820-5.

・ Kitaichi M, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J. 1998 ; 12 : 89-96.

・ Bagan P, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma : A review of the literature. Ann Thorac Surg. 2006 ; 82 : 2010-3.

・ Park MS, et al. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010 ; 22 : 351-5.

・ Martignoni G, et al. PEComas : the past, the present and the future. Virchows Arch. 2008 ; 452 : 119-32.

・ Kenerson H, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007 ; 38 : 1361-71.

・ Hironaka M, Fukayama M. Regional proliferation of HMB-45-positive clear cells of the lung with lymphangioleiomyomatosis-like distribution, replacing the lobes with multiple cysts and a nodule. Am J Surg Pathol. 1999 ; 23 : 1288-93.

・ Muir TE, et al. Micronodular pneumocyte hyperplasia. Am J Surg Pathol. 1998 ; 22 : 465-72.

・ Kobashi Y, et al. Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. Respirology. 2008 ; 13 : 1076-81.

4章胸膜腫瘍の概要と鑑別診断

P.232 掲載の参考文献

・ Hanau CA, Miettinen M. Solitary fibrous tumor : histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995 ; 26 : 440-9.

・ van de Rijn M, et al. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol. 1994 ; 18 : 814-20.

・ Travis WD, et al. Mesenchymal tumours. In : Travis WD, et al. editors. WHO Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC Press ; 2004. p. 141-4.

・ England DM, et al. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989 ; 13 : 640-58.

・ Briselli M, et al. Solitary fibrous tumors of the pleura : eight new cases and review of 360 cases in the literature. Cancer. 1981 ; 47 : 2678-89.

・ Ordonez NG. Localized (solitary) fibrous tumor of the pleura. Adv Anat Pathol. 2000 ; 7 : 327-40.

・ Cardillo G, et al. Localized (solitary) fibrous tumors of the pleura : an analysis of 55 patients. Ann Thorac Surg. 2000 ; 70 : 1808-12.

・ Dedrick CG, et al. Computed tomography of localized pleural mesothelioma. Am J Roentgenol. 1985 ; 144 : 275-80.

・ Chaugle H, et al. Hypoglycaemia associated with a solitary fibrous tumour of the pleura. Eur J Cardiothorac Surg. 1999 ; 15 : 84-6.

・ Chamberlain MH, Taggart DP. Solitary fibrous tumor associated with hypoglycemia : an example of the Doege-Potter syndrome. J Thorac Cardiovasc Surg. 2000 ; 119 : 185-7.

・ Chan JK. Solitary fibrous tumour--everywhere, and a diagnosis in vogue. Histopathology. 1997 ; 31 : 568-76.

・ Vallat-Decouvelaere AV, et al. Atypical and malignant solitary fibrous tumors in extrathoracic locations : evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998 ; 22 : 1501-11.

・ Brunnemann RB, et al. Extrapleural solitary fibrous tumor : a clinicopathologic study of 24 cases. Mod Pathol. 1999 ; 12 : 1034-42.

・ Hasegawa T, et al. Extrathoracic solitary fibrous tumors : their histological variability and potentially aggressive behavior. Hum Pathol. 1999 ; 30 : 1464-73.

・ Suster S, et al. Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol. 1995 ; 19 : 1257-66.

・ Dorfman DM, et al. Solitary fibrous tumor of the orbit. Am J Surg Pathol. 1994 ; 18 : 281-7.

・ Young RH, et al. Solitary fibrous tumors ('fibrous mesotheliomas') of the peritoneum. A report of three cases and a review of the literature. Arch Pathol Lab Med. 1990 ; 114 : 493-5.

・ Witkin GB, Rosai J. Solitary fibrous tumor of the mediastinum. A report of 14 cases. Am J Surg Pathol. 1989 ; 13 : 547-57.

・ Yousem SA, Flynn SD. Intrapulmonary localized fibrous tumor. Intraparenchymal socalled localized fibrous mesothelioma. Am J Clin Pathol. 1988 ; 89 : 365-9.

・ Hasegawa T, et al. Solitary fibrous tumor of the soft tissue. An immunohistochemical and ultrastructural study. Am J Clin Pathol. 1996 ; 106 : 325-31.

・ Suster S, et al. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol. 1998 ; 22 : 863-72.

・ Chilosi M, et al. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol. 1997 ; 181 : 362-7.

・ Flint A, Weiss SW. CD-34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma. Hum Pathol. 1995 ; 26 : 428-31.

・ Hasegawa T, et al. Frequent expression of bcl-2 protein in solitary fibrous tumors. Jpn J Clin Oncol. 1998 ; 28 : 86-91.

・ Yokoi T, et al. Solitary fibrous tumour : significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology. 1998 ; 32 : 423-32.

・ Granville L, et al. Review and update of uncommon primary pleural tumors : a practical approach to diagnosis. Arch Pathol Lab Med. 2005 ; 129 : 1428-43.

・ Churg A, et al. Solitary fibrous tumor and malignant version of solitary fibrous tumor. In : Churg A, et al. editors. Tumors of the Serosal Membranes, AFIP Atlas of Tumor Pathology, 4th series, fascicle 3. Washington DC : Armed Forces Institute of Pathology ; 2006. p. 103-6, 119-21.

P.238 掲載の参考文献

・井内康輝. 中皮腫-病理組織所見の見方. 井内康輝監修. 画像と病理像から学ぶ中皮腫アトラス. 東京 : 篠原出版新社 ; 2009. p.236-46.

・ Kushitani K, Takeshima Y, et al. Immunohistochemical marker panels for distinguishing between mesothelioma and lung adenocarcinoma. Pathol Int. 2007 ; 57 (4) : 190-9.

・ Kushitani K, Takeshima Y, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathology Int. 2008 ; 58 (2) : 75-83.

・ Takeshima Y, Amatya VJ, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol. 2008 ; 130 : 771-9.

・ Takeshima Y, Amatya VJ, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009 ; 54 : 667-76.

P.247 掲載の参考文献

・ Adams VI, Unni KK, et al. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986 ; 58 : 1540-51.

・ Boutin C, Rey F, et al. Thoracoscopy in pleural malignant mesothelioma : a prospective study of 188 consecutive patients. Part 2 : Prognosis and staging. Cancer. 1993 ; 72 : 394-404.

・ Sugarbaker DJ, Mentzer SJ, et al. Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg. 1992 ; 54 : 941-6.

・ Churg A, Colby TV, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000 ; 24 : 1183-200.

・ Travis WD, Brambilla E, et al. Tumours of the Lung, Pleura, Thymus and Heart (World Health Organization Classification of Tumours). Lyon : IARC press ; 2004.

・ Churg A, Cagle PT, et al. Tumors of the serosal membranes. AFIP Atlas of Tumor Pathology Series 4, vol.3 American Registry of Pathology in Collaboration with the Armed Forces Institute of Pathology ; Washington DC : 2006.

・ Whitaker D, Henderson DW, et al. The concept of mesothelioma in situ : implications for diagnosis and histogenesis. Semin Diagn Pathol. 1992 ; 9 : 151-61.

・ Henderson DW, Shilkin KB, et al. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ : a brief review. Am J Clin Pathol. 1998 ; 110 : 397-404.

・ Bolen JW, Hammar SP, et al. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural, and immunocytochemical study. Am J Surg Pathol. 1986 ; 10 : 34-47.

・ Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005 ; 353 : 1591-603.

・ Robinson BWS, Chahinian AP, (eds). Mesothelioma. London : Martin Dunitz Ltd ; 2002.

・亀井敏昭, 石川雄一ほか編. アスベストと中皮腫. 東京 : 篠原出版新社 ; 2007.

・ Lopez-Rios F, Illei PB, et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004 ; 364 : 1157-66.

・ Rusch VW : A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996 ; 14 : 1-12.

・ Rusch A. Proposed new international TNM staging system for malignant pleural mesotheioma. From the International Mesothelioma Interest Group. Chest. 1995 ; 108 : 1122-36.

・ Tammilehto L, Kivisaari L, et al. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma : an assessment in 88 patients. Lung Cancer. 1995 ; 12 : 25-34.

・ Petterson T, Froseth B, et al. Concentration of hyaluronic acid in pleural fluid as diagnostic aid for malignant mesothelioma. Chest. 1988 ; 94 : 1037-9.

・井内康輝監. 画像と病理像から学ぶ中皮腫アトラス. 東京 : 篠原出版新社 ; 2009.

・ Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008 ; 132 : 397-401.

・ Cury PM, Butcher DN, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999 ; 189 : 251-7.

・ Saad RS, Cho P, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma : a comparative study. Diagn Cytopathol. 2005 ; 32 : 156-9.

・ Sato A, Torii I, et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010 ; 23 : 1458-66.

・ Kato Y, Tsuta K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007, 20 : 215-20.

・ Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol. 1994 ; 25 : 753-7.

・ Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010 ; 101 : 1-6.

・ Takeda M, Kasai T, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010 ; 60 : 395-9.

・ Savic S, Franco N, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010 ; 138 : 137-44.

P.259 掲載の参考文献

・ Churg A, Cagle PT, et al. Separation of benign and malignant mesothelial proliferations, Tumors of the Serous Membrane. Washington DC : ARP press ; 2006, p.83-102.

・亀井敏昭. 反応性中皮. 亀井敏昭ほか編. アトラス細胞診と病理診断. 東京 : 医学書院 ; 2010. p.132-5.

・武島幸男, 櫛谷桂ほか. 胸膜悪性中皮腫の組織診断 (1) 反応性病変との鑑別. 病理と臨床. 2010 ; 28 : 288-93.

・ Tsukiji H, Takeshima Y, et al. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma and non-neoplastic mesothelial cells. Histopathology. 2010 ; 56 : 968-82.

P.265 掲載の参考文献

・ Staging Manual in Thoracic Oncology. Goldstraw P, FRCS, Executive Editor, Editorial Rx Press, USA : 2009.

・ Attanoos RL, et al. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals. Histopathology. 2003 ; 43 : 387-92.

・ Koss MN, et al. Adenocarcinoma simulating mesothelioma : a clinicopathologic and immunohistochemical study of 29 cases. Ann Diagn Pathol. 1998 ; 2 : 93-102.

・ Attanoos RL, Gibbs AR. 'Pseudomesotheliomatous' carcinomas of the pleura : a 10-year analysis of cases from the environmental lung disease research group, Cardiff. Histopathology. 2003 ; 43 : 444-52.

・ Roviaro GC, et al. The association of pleural mesothelioma and tuberculosis. Am Rev Respir Dis. 1982 ; 126 : 569-71.

・ Attanoos RL, et al. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology. 2002 ; 41 : 42-9.

・ Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma : a comparative study. Hum Pathol. 2004 ; 35 : 697-710.

・ Matthay RA, et al. Malignancies metastatic to the pleura. Invest Radiol. 1990 ; 25 : 601-9.

・ Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol. 2006 ; 30 : 3-17.

・ Ordonez NG. The immunohistochemical diagnosis of mesothelioma. A Comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003 ; 27 : 1031-51.

・ King JE, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma : a detailed systematic analysis using published data. Histopathology. 2006 ; 48 : 223-32.

・ Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007 ; 38 : 1-16.

・ Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types. An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003 ; 27 : 150-8.

・ Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung : a comparative study. Mod Pathol. 2006 ; 19 : 417-28.

・ Kushitani K, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008 ; 58 : 75-83.

・ Takeshima Y, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009 ; 54 : 667-76.

・ Pan C, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003 ; 34 : 1155-62.

・ Butnor KJ, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006 ; 130 : 823-7.

・ Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol. 2006 ; 13 : 316-29.

・ Hammar SP, et al. Mucin-positive epithelial mesotheliomas : a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.Ultrastruct Pathol. 1996 ; 20 : 293-325.

P.272 掲載の参考文献

・ Fletcher CDM, et al., editors. WHO classification of tumours. Pathology and genetics. Tumours of soft tissue and bone. Lyon : IARC Press ; 2002.

・ Gaertner E, et al. Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. Am J Surg Pathol. 1996 ; 20 : 36-45.

・ Miettinen M, et al. Calretinin and other mesothelioma markers in synovial sarcoma : analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001 ; 25 : 610-7.

・ Lucas DR, et al. Sarcomatoid mesothelioma and its histological mimics : a comparative immunohistochemical study. Histopathology. 2003 ; 42 : 270-9.

・ Matsuyama A, et al. TLE1 expression in malignant mesothelioma. Virchows Arch. 2010 ; 457 : 577-83.

・ Zhang PJ, et al. Malignant epithelioid vascular tumors of the pleura : report of a series and literature review. Hum Pathol. 2000 ; 31 : 29-34.

・ Lin BT, et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases. Am J Surg Pathol. 1996 ; 20 : 1431-9.

・ Moran CA, et al. Smooth muscle tumours of the pleura. Histopathology. 1997 ; 30 : 97-8.

・ Kung IT, et al. Expression of muscle actins in diffuse mesotheliomas. Hum Pathol. 1995 ; 26 : 565-70.

・ Bhattacharya B, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005 ; 29 : 653-9.

・ Joshi A, et al. Clear cell sarcoma mimicking malignant pleural mesothelioma. Histopathology. 2008 ; 53 : 359-61.

・ Goetz SP, et al. Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma. Am J Clin Pathol. 1992 ; 97 : 498-502.

・ Benchetritt M, et al. Dedifferentiated liposarcoma of the pleura mimicking a malignant solitary fibrous tumor and associated with dedifferentiated liposarcoma of the mediastinum : usefulness of cytogenetic and molecular genetic analyses. Cancer Genet Cytogenet. 2007 ; 179 : 150-5.

・ Klebe S, et al. Malignant mesothelioma with heterologous elements : clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008 ; 21 : 1084-94.

★ Weiss SW, Goldblum JR, editors. Enzinger and Weiss's soft tissue tumors, 5th ed. St Louis : Mosby ; 2007.

6章病理検体の取り扱い

P.304 掲載の参考文献

・ Churg A. An inflation procedure for open lung biopsies. Am J Surg Pathol. 1983 ; 7 : 69-71.

・ Farrell DJ, et al. Tissue artefacts caused by sponges. J Clin Pathol. 1992 ; 45 : 923-4.

・ Fraire AE, et al. Transbronchial lung biopsy. Histopathologic and morphometric assessment of diagnostic utility. Chest. 1992 ; 102 : 748-52.

・ Gibbs AR, Attanoos RL. Examination of lung specimens. J Clin Pathol. 2000 ; 53 : 507-12.

・ Kendall DM, Gal AA. Interpretation of tissue artifacts in transbronchial lung biopsy specimens. Ann Diagn Pathol. 2003 ; 7 : 20-4.

・ Popovich J, Jr., et al. Diagnostic accuracy of multiple biopsies from flexible fiberoptic bronchoscopy. A comparison of central versus peripheral carcinoma. Am Rev Respir Dis. 1982 ; 125 : 521-3.

・ Zavala DC. Diagnostic fiberoptic bronchoscopy : Techniques and results of biopsy in 600 patients. Chest. 1975 ; 68 : 12-9.

・岡輝明. 肺の非腫瘍性疾患の病理診断を行うための検体の取り扱いと肺構造の要点. 病理と臨床. 2006 ; 24 : 792-800.

・岡輝明. 肺腫瘍の組織診断正しい診断へのアプローチ肺・胸膜腫瘍生検診断のpitfall. 病理と臨床. 2010 ; 28 : 228-33.

・佐藤之俊, 奥村栄ほか. 正しい外科切除標本の取り扱い方肺の切除標本の取り扱い方. 臨床外科. 2003 ; 58 : 449-55.

・蔦幸治, 横瀬智之ほか. 術中迅速病理診断における肺癌の線維化巣評価の工夫. 病理と臨床. 2004 ; 22 : 91-4.

・吉田浩一, 加藤靖文ほか. 正しい外科切除標本の取り扱い方肺の切除標本の取り扱い方. 臨床外科. 2003 ; 58 : 287-93.

★ Dail and Hammar's pulmonary pathology. Tomashefski JF, Jr., et al. editors. 3rd ed. New York : Springer ; 2008.

★ Tumors of the Lower Respiratory Tract. Colby TV, et al. Atlas of tumor pathology, Third Series. Washington, D. C. : Armed Forces Institute of Pathology ; 1995.

★ Pathology of the lung. Corrin B, Niocholson AG. 2nd ed. Philadelphia : Churchill Livingstone ; 2006.

★ Practical pulmonary pathology. Leslie KO, Wick MR, editors. 1st ed. Philadelphia : Churchill Livingstone ; 2005.

★ Spencer's pathology of the lung. Hasleton PS, editor. 5th ed. New York : McGraw-Hill ; 1996.

★ Surgical pathology of non-neoplastic lung disease. Katzenstein AA. 4th ed. Philadelphia : Saunders Elsevier ; 2006.

★ 外科病理マニュアル. 深山正久ほか編. 病理と臨床 26 臨増. 東京 : 文光堂 ; 2008.

★ 臨床・病理肺癌取り扱い規約【改訂第7版】抜粋. 日本肺癌学会編. http://www.haigan.gr.jp/modules/bulletin/index.php?page=article&storyid=20 ; 2010.

7章症例の実際

P.312 掲載の参考文献

・ Soda M, Choi YL, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 ; 448 : 561-6.

・ Choi YL, Takeuchi K, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008 ; 68 : 4971-6.

・ Takeuchi K, Choi YL, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008 ; 14 : 6618-24.

・ Takeuchi K, Choi YL, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009 ; 15 : 3143-9.

・ Inamura K, Takeuchi K, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009 ; 22 : 508-15.

・ Inamura K, Takeuchi K, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008 ; 3 : 13-7.

P.316 掲載の参考文献

・ Amin MB, et al. Micropapillary component in lung adenocarcinoma : a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002 ; 26 : 358-64.

・ Hashimoto T, et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors : evidence from p53 mutation spectra. Am J Pathol. 2000 ; 157 : 2133-41.

・ Hsieh RK, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 2005 ; 128 : 317-21.

・ Kim YH, et al. Dominant papillary subtype is significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 2004 ; 10 : 7311-7.

・ Miller VA, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004 ; 22 : 1103-9.

・ Miyoshi T, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol. 2003 ; 27 : 101-9.

・ Ninomiya H, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas : significance of the micropapillary pattern and the hobnail cell type. Lung Cancer. 2009 ; 63 : 235-40.

・ Paez JG, et al. EGFR mutation in lung cancer : correlation with clinical response to gefitinib therapy. Science. 2004 ; 304 : 1497-500.

・ Pao W, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004 ; 101 : 13306-11.

・ Shigematsu H, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 ; 97 : 339-46.

・ Yatabe Y, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005 ; 29 : 633-9.

P.326 掲載の参考文献

・ Hashimoto T, et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors : evidence from p53 mutation spectra. Am J Pathol. 2000 ; 157 : 2133-41.

・ Takahashi T, et al. Expression and alteration of Ras and P53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer. 2002 ; 95 : 624-33.

・ Olson AL, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007 ; 176 : 277-84.

・ Ozawa Y, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009 ; 14 : 723-8.

・井上哲郎ほか. 臨床症状と身体所見. 日胸. 2003 ; 62 : S32-7.

・ Minegishi Y, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009 ; 48 : 665-72.

・ Watanabe A, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thoracic Cardiovasc Surg. 2008 ; 136 : 1357-63.

・青山克彦ほか. 肺線維化病変合併肺癌症例の術後急性増悪に対するステロイド予防投与. 臨床呼吸生理. 2003 ; 35 : 123-6.

・千田雅之ほか. 限局性間質性肺炎からの肺癌手術後急性増悪例の検討. 胸部外科. 2005 ; 58 : 22-5.

・ American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory society International Multidisciplinary Consensus Classification of the Idiopathic International Pneumonias. Am J Respir Crit Care Med. 2002 ; 165 : 277-304.

P.332 掲載の参考文献

・ Broers JL, et al. Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens. Cancer Res. 1987 ; 47 : 3225-34.

・ Folpe AL, et al. Thyroid transcription factor-1 : immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999 ; 12 : 5-8.

・ Guinee DG Jr, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol. 1994 ; 102 : 406-14.

・ Hiroshima K, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma : a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006 ; 19 : 1358-68.

・ Jerome Marson V, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours : correlation with histological type and grade. Histopathology. 2004 ; 45 : 125-34.

・ Jiang SX, et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol. 2004 ; 17 : 222-9.

・ Nicholson SA, et al. Small cell lung carcinoma (SCLC) : a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002 ; 26 : 1184-97.

・ Nitadori J, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006 ; 125 : 682-92.

P.336 掲載の参考文献

・ Iyoda A, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001 ; 91 : 1992-2000.

・ Takei H, et al. Large cell neuroendocrine carcinoma of the lung : a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002 ; 124 : 285-92.

・ Asamura H, et al. Neuroendocrine neoplasms of the lung : a prognostic spectrum. J Clin Oncol. 2006 ; 24 : 70-6.

・ Rossi G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005 ; 23 : 8774-85.

・ Iyoda A, et al. Pulmonary large cell carcinomas with neuroendocrine features are highgrade neuroendocrine tumors. Ann Thorac Surg. 2002 ; 73 : 1049-54.

・ Iyoda A, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg. 2006 ; 132 : 312-5.

・ Iyoda A, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006 ; 82 : 1802-7.

・ Hiroshima K, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma : a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006 ; 19 : 1358-68.

・ Travis WD, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 ; 15 : 529-53.

・ Nitadori J, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006 ; 125 : 682-92.

・ Casali C, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2004 ; 77 : 247-52 ; discussion 52-3.

・ Hiroshima K. Small cell carcinoma : Distinction from large cell neuroendocrine carcinoma. In : Maldonado JG, Cervantes MK, editors. Small Cell Carcinomas : Causes, Diagnosis and Treatment. New York : Nova Science Publishers ; 2009. p. 101-21.

P.340 掲載の参考文献

・ Cantin R, Al-Jabi M, et al. Desmoplastic diffuse mesothelioma. Am J Surg Pathol. 1982 ; 6 : 215-22.

書評

書評を投稿する

最近チェックした商品履歴

Loading...